Testing Elacestrant With Other Targeted Drugs for Metastatic Breast Cancer

Findings from the phase Ib/II ELEVATE trial presented at the San Antonio Breast Cancer Symposium demonstrated the potential of the oral selective estrogen receptor degrader elacestrant (Orserdu) in combination with various targeted agents — including abemaciclib (Verzenio), palbociclib (Ibrance), and everolimus — for the treatment of metastatic breast cancer.

In this exclusive MedPage Today video, Hope Rugo, MD, of the University of California San Francisco, discusses results and progress of the ongoing umbrella trial.

Following is a transcript of her remarks:

So ELEVATE is this umbrella trial combining elacestrant with all of the target agents we can think of. So, ribociclib is still in the dose-finding area. Abemaciclib has completed phase II. Palbociclib is ready to go in dose expansion at full dose of 125 mg. Everolimus, the RP2D [recommended phase II dose] is 7.5 milligrams of everolimus with full dose elacestrant, and so that’s also in phase II, that 30-patient, efficacy-focused part of ELEVATE.

Alpelisib, we ran into a lot of toxicities, but they were all alpelisib toxicities. So a lower dose will be tested in the next cohort with elacestrant. And then capivasertib [Truqap] is in the early part of dose escalation in combination, but so far going very well and well tolerated without any notable toxicities.

And I think those are all of the agents. So we finished abema phase II, but all the others are either enrolling or still finishing the dose finding, but very close to being finished. So then we can study other novel combinations as well. And I’m looking forward to our next efficacy output from ELEVATE and how we can further explore these combinations, because they seem to be very well tolerated and so far are showing the side effects that are related to the targeted agent and very nice efficacy data.

Please enable JavaScript to view the comments powered by Disqus.